Saranna Fanning is an Assistant Professor of Neurology at Harvard Medical School and Brigham & Women’s Hospital. She received her BSc degree from the National University of Ireland, Cork and performed her doctoral research work at Columbia University, Carnegie Mellon, and the National University of Ireland, Cork (Degree awarding University). Dr. Fanning performed her postdoctoral training on neurodegenerative disease protein toxicity with Dr. Susan Lindquist at the Whitehead Institute for Biomedical Research, MIT. She joined the Department of Neurology and Ann Romney Center for Neurologic Diseases at Brigham & Women’s hospital in 2017. Dr. Fanning is focused on understanding complex genetic interactions impacting disease and identifying therapeutic targets for Parkinson’s disease, Lewy Body Dementia and other synucleinopathies. Her lab seeks to understand the role of the metabolome in disease. Specifically, Dr. Fanning focuses on the role of cellular lipid dysregulation in Parkinson’s disease and identifying therapeutic targets in lipid pathways.
Associated Grants
-
RNAi Therapeutics Targeting Stearoyl-CoA-Desaturase as a Disease-modifying Treatment for Parkinson’s Disease
2025
-
-
Targeting the Interaction of Alpha-synuclein with Lipids as a Therapeutic for Parkinson’s Disease
2022
-
Targeting Brain-specific Stearoyl-CoA-Desaturase 5 (SCD5) as a Treatment for Parkinson’s Disease
2021